Cardiac resynchronisation therapy: Evidence based benefits and patient selection
- 31 May 2008
- journal article
- review article
- Published by Elsevier BV in European Journal of Internal Medicine
- Vol. 19 (3), 165-172
- https://doi.org/10.1016/j.ejim.2007.09.012
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Delivering the cumulative benefits of triple therapy to improve outcomes in heart failureJournal of the American College of Cardiology, 2003
- Effect of Carvedilol on Survival in Severe Chronic Heart FailureThe New England Journal of Medicine, 2001
- Is the prognosis of heart failure improving?Journal of the American College of Cardiology, 2000
- Effects of Controlled-Release Metoprolol on Total Mortality, Hospitalizations, and Well-being in Patients With Heart FailureJAMA, 2000
- The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart FailureThe New England Journal of Medicine, 1999
- The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trialThe Lancet, 1999
- Risk stratification in chronic heart failureEuropean Heart Journal, 1998
- Effect of Enalapril on Survival in Patients with Reduced Left Ventricular Ejection Fractions and Congestive Heart FailureThe New England Journal of Medicine, 1991
- Cardiac failure and sudden death in the Framingham StudyAmerican Heart Journal, 1988
- Effects of Enalapril on Mortality in Severe Congestive Heart FailureThe New England Journal of Medicine, 1987